News
This phase II study demonstrated the efficacy of osimertinib 80 mg daily in patients with EGFR mutant NSCLC with leptomeningeal disease. The study designed included BICR using the RANO-LM assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback